New FDA guidelines for personalized genomic drug development are a step forward in advancing new therapies for ultrarare diseases, but industry leaders need further clarification.
In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.
SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a ...
Broadcast Retirement Network's Jeffrey Snyder discusses the use of Artificial Intelligence in the creation of new drug with Early-Stage Biotech Scientist Andrew R. Snyder, PhD. Jeffrey Snyder, ...
Molecule AI is revolutionising drug discovery by using artificial intelligence to predict molecular combinations and ...
Clinical trials are not just about testing medicines; they are about building the future of healthcare There is a dire need for awareness about clinical research in India to deliver innovative safe an ...
The FDA has opened the door to the use of Bayesian statistical methods in clinical trials. The worry: Introducing ...
Demis Hassabis is the co-founder and CEO of Google DeepMind, an AI research laboratory responsible for development of the Gemini large language model and AlphaFold, a system that revolutionized the ...
Elli Lilly has been in the news lately because of the announced $1 billion investment in a joint innovation lab with Nvidia, an AI powerhouse player. But AI drug discovery is only part of the story of ...
Collateral Damage for the Coal Industry? Pharma Ad Scrutiny a Test for Free Speech Sue-Pervised Retirement Navigating the GOP Divide over Artificial Intelligence Lawfare Is the Climate Warriors’ Best ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results